Etna (Evaluating Treatment With Neoadjuvant Abraxane) Randomized Phase Iii Study Comparing Neoadjuvant Nab-Paclitaxel (Nab-P) Versus Paclitaxel (P) Both Followed By Anthracycline Regimens In Women With Her2-Negative High-Risk Breast Cancer: A Michelango Study.